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meet the ambition of the Drug 
Strategy 2010 to help more heroin 
users to recover and break free of 
dependence…”
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I am honoured to have been invited to chair the expert group on recovery orientated drug treatment. I have been 
helped enormously by the commitment and goodwill of the wide range of experienced colleagues from across 
the field who came together for this important task. I would like to take this opportunity to thank them all.
Our work has involved a re-examination of treatment methods and objectives that can help the recovery of those 
with addiction problems. This is an important step in meeting the ambitions of the people who use our services 
and of the government’s Drug Strategy 2010.
We have embarked on this work with the advantage of the considerable expertise of the group’s members and 
a substantial international scientific literature. We have sought to use this knowledge to set a new benchmark 
for the English treatment system that is both radically ambitious and scientifically rigorous. We are not alone in 
this endeavour, and important steps have already been made by international colleagues, such as US addiction 
experts Tom McLellan and Bill White, to whom we owe a debt of gratitude and from whom a commentary on 
our work is being published in conjunction with the report.
On behalf of the expert group, I would like to thank the NTA for its secretariat and support, and government 
departments for their support for our work.
Finally, I am acutely aware that delivering this ambition will depend on the continued professionalism and 
commitment of practitioners, and the development of systems that integrate clinical care with the wide range 
of services required to deliver long-term recovery. It will also depend crucially on the quality of shared vision 
and effort from those who are (or have been) dependent on drugs, their families and communities, and on the 
government’s continued determination to tackle this important challenge. Our report describes how more can be 
achieved: the task is now to achieve it.
John Strang, July 2012
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EXECUTIVE SUMMARY
1. Investment in drug treatment since 2001 has 
given more people access to long-term, high-
quality treatment, which has substantially 
improved their health. The task of the Recovery 
Orientated Drug Treatment Expert Group has 
been to describe how to meet the ambition of 
the Drug Strategy 2010 to help more heroin users 
to recover and break free of dependencea. Heroin 
users are the largest single group in treatment 
and use an especially tenacious, habit-forming 
drug in the most dangerous ways.
2. Entering and staying in treatment, coming off 
opioid substitution treatment (OST) and exiting 
structured treatment are all important indicators 
of an individual’s recovery progress, but they do 
not in themselves constitute recovery. Coming off 
OST or exiting treatment prematurely can harm 
individuals, especially if it leads to relapse, which 
is also harmful to society. Recovery is a broader 
and more complex journey that incorporates 
overcoming dependence, reducing risk-taking 
behaviour and offending, improving health, 
functioning as a productive member of society 
and becoming personally fulfilled. These recovery 
outcomes are often mutually reinforcing.
3. The ambition for more people to recover is 
legitimate, deliverable and overdue. Previous drug 
strategies focused on reducing crime and drug-
related harm to public health, where the benefit 
to society accrued from people being retained in 
treatment programmes as much from completing 
them. However, this allowed a culture of 
commissioning and practice to develop that gave 
insufficient priority to an individual’s desire to 
overcome his or her drug or alcohol dependence.
4. This has been particularly true for heroin users 
receiving OST, where the protective benefits have 
too often become an end in themselves rather 
than providing a safe platform from which users 
might progress towards further recovery.
5. Overcoming drug or alcohol dependence is often 
difficult. Only half of established smokers in 
England are likely to make a long-term recovery 
from tobacco dependence1. In the USA, up to 
half of the alcohol-dependent population can 
expect to recover over the long term2. Heroin and 
other opiates have a far worse prognosis: long-
term USA studies suggest that, over 30 years, half 
of dependent users will die, one fifth will recover 
and the remainder will continue to use opiates, 
albeit some at a lower level3.
6. The existence of an accessible, evidence-based, 
drug treatment system in every part of England 
gives us an excellent opportunity to improve on 
the past by using international, historical evidence 
as the floor for our ambition and not its ceiling.
7. England has lower rates of drug-related deaths 
and blood-borne virus infections than most of our 
European and North American neighbours. Most 
people who enter treatment want to recover and 
break free of their drug dependence. We can help 
more to realise this ambition if we can ally safe, 
evidence-based recovery-orientated practice to the 
public health and wider social benefits we already 
accrue from treatment.
8. According to the research, the international track 
record and clinical experience, not everyone 
who comes into treatment will overcome their 
dependence. We know from the same sources 
that it is not possible or ethical to predict 
which individuals will eventually overcome their 
dependence. This is why we are obliged to create 
a treatment system that makes every effort to 
provide the right package of support to maximise 
every individual’s chances of recovery.
9. Fewer young people are now coming into 
treatment for dependence on the most 
damaging drugs such as heroin, but there 
is an ageing cohort of drug dependent and 
ex-dependent individuals who will experience 
an increase in morbidity and mortality as they 
develop multisystem diseases that need complex 
treatment. Primary and secondary care services 
will be needed to treat them.
10. The Chair’s interim report in July 2011 (Strang, 
2011) was well-received and with support 
from the NTA has already resulted in practice 
improvements. This final report of the expert 
group details our collective view of how we go 
about channelling the energy and commitment 
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of service users, commissioners and practitioners 
to achieve world-class recovery outcomes.
11. Well-delivered OST provides a platform of stability 
and safety that protects people and creates the 
time and space for them to move forward in 
their personal recovery journeys. OST has an 
important and legitimate place within recovery-
orientated systems of care. The drug strategy is 
clear that medication-assisted recovery can and 
does happen. We need to ensure OST is the 
best platform it can be, but focus equally on the 
quality, range and purposeful management of the 
broader care and support it sits within.
12. If we stick closely to the compelling evidence 
for effective OST, and the existing guidance 
based upon that evidence, we will deliver many 
of the improvements needed – but we can and 
should do more. A determined assessment of 
the shortfalls in provision, followed by remedial 
action, is a priority if OST is to fulfil its potential in 
supporting recovery.
13. There is no justification for poor-quality treatment 
anywhere in the system. It is not acceptable to 
leave people on OST without actively supporting 
their recovery and regularly reviewing the 
benefits of their treatment (as well as checking, 
responding to, and stimulating their readiness for 
change). Nor is it acceptable to impose time-
limits on their treatment that take no account of 
individual history, needs and circumstances, or 
the benefits of continued treatment. Treatment 
must be supportive and aspirational, realistic and 
protective.
14. Some people have a level of personal and other 
resources (called ‘recovery capital’) that enables 
them to stabilise and leave treatment more 
quickly than others. Many others have long-term 
problems and complex needs, meaning their 
recovery may take much longer and they require 
help to build their recovery capital. Treatment 
given over this timescale must maintain its 
recovery orientation.
15. Arbitrarily or prematurely curtailing an individual’s 
OST will not help them sustain their recovery and 
is not in the interests of the wider community 
either. It risks losing any advances because it 
is externally imposed and so has no meaning 
– the individual does not own the decision. 
This would likely lead to an increase in blood-
borne virus rates, drug-related deaths and 
crime. However, clear and ambitious goals, with 
timescales for action, are key components of 
effective individualised treatment, especially 
when the individual collaborates in planning 
them. We strongly support continued reference 
and adherence to the existing NICE drug misuse 
guidance (reviewed and unchanged in 2010-11) 
and to the more practitioner-orientated 2007 
Clinical Guidelines.
16. The more ambitious approach outlined will 
sometimes lead to people following a potentially 
more hazardous path, with the risk of relapse 
(or at least occasional lapse) as they seek to 
disengage from the OST that has supported 
them. Individuals (and their families), clinicians 
and services need to understand this potential 
risk. They need to approach the change with 
careful planning and increased support, and 
include a ‘safety-net’ in case of relapse.
17. OST will improve as a result of changes at a 
system, service and individual level. These include:
• treatment systems and services having a 
clear and coherent vision and framework 
for recovery that are visible to people in 
treatment, owned by all staff and maintained 
by strong leadership
• purposeful treatment interventions that 
are properly assessed, planned, measured, 
reviewed and adapted
• ‘phased and layered’ interventions that 
reflect the different needs of people at 
different times
• treatment that creates the therapeutic 
conditions and optimism in which people, 
and especially those with few internal and 
external resources, can meet the challenge 
of initiating and maintaining change
• OST programmes that optimise the 
medication according to the evidence and 
guidance
• measuring recovery by assessing and 
tracking improvements in severity, complexity 
and recovery capital, then using this 
information to tailor interventions and 
support that boost an individual’s chances of 
recovering and improve his or her progress 
towards that goal
• treatment services that are not expected 
to deliver recovery on their own but are 
integrated with, and benefit from, other 
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services such as mutual aid, employment 
support and housing
• treatment that works alongside peers and 
families to give people direct access to, 
or signposts and facilitated support to, 
opportunities to reduce and stop their drug 
use, improve their physical and mental 
health, engage with others in recovery, 
improve relationships (including with their 
children), find meaningful work, build key 
life skills, and secure housing.
a. “The investment made in the drug treatment system over 
the last decade has built capacity and enabled people to 
access treatment for a sufficient period of time to bring about 
substantial health gains. We now need to … become much 
more ambitious for individuals to leave treatment free of their 
drug or alcohol dependence” Drug Strategy 2010 – ‘Reducing 
Demand, Restricting Supply, Building Recovery: Supporting 
People to Live a Drug Free Life.’ 
1. Etter and Stapleton, 2006; Stapleton J, personal 
communication, 14 June 2012
2. Dawson et al., 2005; Ojesjö, 1981; Schutte et al., 2003; 
Vaillant, 2003
3. Calabria et al., 2010; Darke, 2011; Degenhardt et al., 2010; 
Grella and Lovinger, 2011; Hser, 2007 
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IMPLEMENTING RECOVERY ORIENTATED 
OPIOID SUBSTITUTION TREATMENT
Professor John Strang’s 2011 interim report on our 
work (www.nta.nhs.uk/uploads/rodt_an_interim_
report_july_2011.pdf) described some immediate steps 
to improve the recovery-orientation of treatments such 
as prescribing, and to ensure people in treatment get 
appropriate support to achieve the best gains. Set out 
below, these still provide a good starting point. They 
are followed by additional principles and prompts of 
recovery-orientated drug treatment that commissioners 
and providers can use to test progress.
Immediate steps to improve recovery orientation
1. Audit the balance in your service between 
overcoming dependence and reducing harm 
to ensure both objectives properly coexist; and 
that individual clinicians understand and apply a 
personalised assessment for each patient, regularly 
repeat it, and, based on its findings, re-examine 
and adjust the treatment plan with the patient.
2. Review all your patients to ensure they have 
achieved abstinence from their identified problem 
drug(s) or are working to achieve abstinence. 
Patients should be offered the opportunity to 
come off medication after appropriate careful 
planning, when they are ready.
3. Consider whether to change the current balance 
between promoting overcoming of dependence 
and promoting reduction of harms, with the aim 
of actively encouraging more patients to take 
opportunities to recover. Although no clinician 
should take unwarranted risk, neither should they 
protect patients to the extent that they are not 
encouraged and enabled to get better. This must 
always be undertaken in a way that supports 
each patient to make an informed choice that is 
relevant to their personal situation and is based on 
an accurate description of the available options.
4. Ensure exits from treatment are visible to patients 
from the minute they walk through the door of 
your service. This means giving them enough 
information to understand what might comprise 
a treatment journey, even if their eventual exit 
appears some way off. And make visible those 
people who have successfully exited by explicitly 
linking your service to a recovery community, or 
employing  former service users or using them as a 
volunteer recovery mentors and coaches.
5. If agonist or antagonist medications are being 
prescribed, then review, jointly with each patient 
and with input, as appropriate, from relevant third 
parties, the extent of benefit still being obtained.
6. For patients who have achieved stability while on 
medication and who choose to reduce and/or stop 
the medication, ensure that support mechanisms 
are in place to support this transition, and also 
ensure that rapid re-capture avenues are in place 
and are understood and acceptable to the patient, 
in the event of failure of the transition.
7. Check that all treatment is optimised so 
patients are receiving the range and intensity of 
interventions that will give them the best chance 
of recovery. This may include optimised doses 
of appropriate medications; the reintroduction, 
reduction or dropping of supervised consumption 
as appropriate; active keyworking, including case 
management and psychosocial interventions that 
keyworkers are competent to provide; access 
to other psychosocial interventions requiring 
additional competences; etc. As a first step, 
audit the availability of key NICE-recommended 
psychosocial interventions, using the audit tool in 
the NTA/BPS Toolkit.
8. Strengthen or develop patients’ social networks, 
involving families where appropriate and 
facilitating access to mutual aid by, for example, 
providing information, transport, or premises 
for meetings, and by bringing local recovery 
champions into the service to meet patients.
9. Establish opportunities to accrue ‘social capital’ 
via work experience placements or employment, 
training opportunities, volunteer work, etc.
10. Ensure all keyworkers are trained and supervised 
to deliver psychosocial interventions of a type 
and intensity appropriate to their competence. 
Effective keyworking entails recovery care 
planning, case management, advocacy and risk 
management, and collaborative interventions that 
raise the insight and awareness of patients and 
help them plan and build a new life. This will often 
involve attention to employment and housing.
11. Review the quality of your service’s recovery care 
planning and take steps to improve it, where 
possible. Recovery care plans should be personally 
meaningful documents, developed over a period 
of comprehensive assessment, and reviewed and 
adapted regularly, so that they are important to 
and owned by the patient.
12. Ensure your service works with local housing and 
employment services, and with commissioners, to 
ensure there is supported and integrated access to 
relevant provision.
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PRINCIPLES AND FEATURES OF  
RECOVERY-ORIENTATED DRUG TREATMENT
PROMPTS TO TEST WHETHER  
THEY ARE BEING ACHIEVED
FOR COMMISSIONERS
Integrated recovery-orientated systems of care are needed to 
build and maintain recovery
Is a full range of treatment options commissioned, including 
residential rehabilitation, so that there is the necessary 
flexibility to build a range of treatment and recovery 
pathways for different needs: from brief interventions for 
those not needing structured treatment to full packages of 
care-managed pharmacological, psychosocial and recovery 
interventions for those with complex needs?
Arbitrarily curtailing or limiting the use of OST does not 
achieve sustainable recovery and is not in the interests of 
people in treatment or the wider community
• Do contracts avoid imposing arbitrary time limits on 
treatment or elements of it, such as prescribing? 
• Are services expected to set clear and ambitious goals 
for each individual’s treatment, with planned timescales 
for action, and expect targets for general improvements 
in treatment and recovery, such as:  
• increased psychosocial interventions  
• hosting of 12-step meetings  
• development of aftercare functions and peer support?
Drug treatment is not expected to deliver recovery on its own 
but can integrate with and benefit from other support
Is an integrated recovery-orientated system of care being 
created that involved other health and social care services  
with drug treatment  to provide recovery support, including 
mental health, employment, housing, mutual aid, recovery 
communities, etc?
FOR SERVICES
Closer adherence to the compelling evidence for effective 
OST, and the existing guidance based upon it, will deliver 
many of the improvements needed but more can and should 
be done
• Is practice audited (and, where needed, improved) 
against recommendations in the NICE 2007 suite of drug 
misuse guidance (and forthcoming quality standards) 
and the 2007 Clinical Guidelines? 
• Do supervisors have the appropriate competences to 
supervise all the techniques or interventions being used 
by the practitioners they are supervising?
Some people entering treatment have a level of personal 
and other resources (often called recovery capital) that will 
enable them to stabilise and leave treatment more quickly 
than others as long as they are provided with the support they 
need. Many others have long-term problems and complex 
needs – their recovery may take a long time and require long-
term treatment to build their recovery capital.
Is recovery capital assessed and then individual treatment 
plans designed that utilise the strengths and aspirations of 
each service user?
Arbitrarily curtailing or limiting the use of OST does not 
achieve sustainable recovery and is not in the interests of 
people in treatment or the wider community
• Are arbitrary time limits for treatment or elements of 
it avoided but clear and ambitious treatment goals set, 
with planned timescales for action and regular reviews? 
• Are service users, peer support and recovery champions 
involved at all levels of organisational planning 
and where appropriate in delivery of peer-based 
interventions and service promotion, e.g. peer support 
available at assessment? 
• Are pathways through and out of treatment made 
visible, for example involving service users in promotion 
of services, developing peer support services, involving 
service users in delivery of groups, promoting recovery 
events, hosting 12 step meetings?
Recovery is made visible, including the ‘hand and footholds’ 
at each stage of recovery through access to peers who are 
perhaps just little further along in their recovery journey
Are opportunities promoted for contact between people in 
treatment and others further in their recovery journeys?
Mutual identification through mutual aid and peer support is 
important
Is access to mutual aid facilitated by advocating for it, 
accompanying service users, providing meeting space, 
attending open meetings, providing or arranging transport, 
etc?
Principles and features of recovery orientated drug treatment and how to test they are being achieved
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FEATURES OF RECOVERY-ORIENTATED DRUG TREATMENT SYSTEMS AND SERVICES
A clear and coherent vision and framework for recovery 
that is visible to people in treatment, owned by all staff and 
maintained by strong clinical leadership.
Does the service participate in the building of communities of 
recovery that overlap with treatment, advocating for mutual 
aid, utilising peer supporters, ensuring recovery is visible to 
service users?
Purposeful treatment interventions that are properly 
assessed, planned, measured, reviewed and adapted.
Are assessment, planning, review and optimisation processes 
all arranged so that treatment is active, individualised, and 
based on a proper understanding (and regular reviews) of an 
individual’s changing problems, needs and strengths?
‘Phased and layered’ interventions that reflect the different 
needs of people at different times.
• Is the service developing a local solution to phasing 
and layering interventions so that, at every point in a 
treatment journey, they can be offered in a way that is 
appropriate to an individual’s stage of recovery and how 
much intervention they need? 
• Is a range of treatment interventions available to meet 
the needs of a range of clients including those with 
more complex needs that may require high intensity 
interventions?
Treatment that creates the therapeutic conditions and 
optimism in which the challenge of initiating and maintaining 
change can be met, especially by those with few internal and 
external resources.
Do managers ensure keyworkers understand how and 
when to use a range of techniques and tools, including goal 
setting, empathetic listening, exploring the impact and 
negative consequences of current behaviour and the benefits 
of change, strategic use of problem recognition to amplify 
ambivalence about the status quo, managing rewards and 
negative contingencies, and involving social networks?
OST programmes that optimise the medication aspect of the 
treatment according to the evidence and guidance.
Are OST programmes audited to ensure: 
• Effective doses of OST are being prescribed as 
recommended in clinical guidance and tailored to the 
individual? 
• Supervised consumption is used as recommended 
in clinical guidance and tailored to the individual to 
minimise risk while enabling opportunities for recovery 
such as self-directed medication, employment, 
childcare?
Recovery measured by assessing and then tracking 
improvements in severity, complexity and recovery capital, 
and by using this information to better understand how to 
tailor interventions and support to improve an individual’s 
chances of and progress in achieving recovery.
Is progress in treatment regularly measured, and responded 
to, through intelligent use of the Treatment Outcomes 
Profile (TOP), drug testing, and measures of dependence, 
change motivation and engagement, skills and participation, 
environment, personality and relationships, risk and 
safeguarding, financial support, etc?
Drug treatment not expected to deliver recovery on its own 
but integrated with and benefiting from other support such as 
mutual aid, employment support and housing.
Has the service developed partnerships, joint working 
protocols and other ways of working with others able 
to provide recovery support, including mental health, 
employment, housing, mutual aid, recovery communities?
Drug treatment – alongside peers and families – that 
provides direct access, signposts and or facilitated support to 
opportunities for reducing and stopping drug use, improving 
physical and mental health, engaging with others in recovery, 
improving relationships (including with children), finding 
meaningful work, building key life skills, and securing 
housing.
Are arrangements in place for access to a broad range of 
recovery supports?
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 1 INTRODUCTION
1.1 In August 2010, the NTA – on behalf of the 
Department of Health – asked Professor John Strang 
to chair a group to guide the drug treatment field 
on the proper use of medications to aid recovery and 
on how the care for those in need of effective and 
evidence-based drug treatment is more fully orientated 
to optimise recovery. This approach was consistent 
with the new drug strategy published in December 
2010 (HMG, 2010) and its focus on recovery. The 
drug strategy made clear the government’s concern 
that “for too many people currently on a substitute 
prescription, what should be the first step on the 
journey to recovery risks ending there” and wanted 
to “ensure that all those on a substitute prescription 
engage in recovery activities”. Our task was to provide 
guidance to clinicians and agencies so they can help 
individuals on opioid substitution treatment (OST) 
achieve their fullest personal recovery, improve support 
for long-term recovery, and avoid unplanned drift into 
open-ended maintenance prescribing.
1.2 The chair published an interim report in July 
2011. This described some of the common ground we 
had found, and suggested how services and systems 
could immediately improve the treatment they offer. 
The report was well-received and, with support from 
the NTA, has already resulted in practice improvements.
1.3 Our next step, promised in the interim report, 
was to be this final report. Our job has been to reflect 
the evidence and contextualise it within the current 
environment and the ambitions of 2010 Drug Strategy: 
framing a clinical consensus for how treatment that 
includes a prescribing component can be made more 
recovery-orientated.
2 A CONCEPTUAL FRAMEWORK FOR 
PROMOTING RECOVERY
2.1 Recovery from drug dependence is an 
“individual, person-centred journey” (HMG, 2010). 
It will often include some element of challenge to 
individuals, especially if their journey involves continued 
drug use or harmful drinking.
2.2 For many people, treatment is an important 
part of their recovery journey. It is a component of 
a broader recovery-orientated system of health and 
social care and support that harnesses the full range 
of individual, social and community assets. Exiting 
structured treatment is an indicator of, or milestone in, 
an individual’s progress in their recovery journey but 
does not in itself constitute recovery. If premature, it 
can be harmful, especially if it leads to relapse.
2.3 The challenge of treatment for the individual 
is in changing entrenched patterns of drug-using 
behaviour. Treatment services’ response to this should 
manifest itself through well-structured and regularly 
reviewed care plans and goals. Behaviour change 
requires concerted effort and focus. It is difficult and 
requires a range of internal and external resources 
to initiate and maintain. Some people have few of 
these resources and, for them, rising to the challenge 
of treatment may be difficult. Keyworkers have a 
crucial role in creating the therapeutic conditions and 
optimism that can help. This will mean doing different 
things with people at different points in the treatment 
journey but could include: goal setting, empathetic 
listening, exploring the impact and negative 
consequences of current behaviour and the benefits 
of change, strategic use of problem recognition to 
amplify ambivalence about their current position 
and behaviour, managing rewards and negative 
contingencies, and involving social networks.
2.4 Treatment services need to create an 
accessible and integrated ‘offer’ of treatment that is 
personalised and optimised to promote and support 
wide recovery objectives for every person in treatment. 
Medication to support abstinence from illicit drugs 
will remain a necessary component of treatment for 
many but medication alone is unlikely to be sufficient 
to support an individual achieving recovery. Neither is 
abstinence alone.
2.5 The way treatment services are organised 
can promote recovery as the norm by exposing people 
in treatment to others who are further on in their 
recovery journeys. Advocating the benefits of mutual 
aid, utilising peer supporters, and participating in 
building communities of recovery will all help. 
2.6 Facilitating an individual’s recovery starts with 
the first treatment contact, harnessing the motivational 
momentum that led to that contact. The subsequent 
recovery journey through treatment is underpinned by 
a comprehensive assessment and recovery care plan 
process, which is regularly reviewed and adapted as 
needed. The aim is for individuals to exit treatment 
with the best possible chance of sustaining and 
building on the gains they have made in treatment. 
2.7 There is a large literature on the concepts 
of recovery and many have defined it, with varying 
degrees of success and acceptance. Work by many 
people and organisations (most notably the Betty Ford 
Institute (2007), UKDPC (2008) and SAMHSA (2011), 
and more broadly the mental health movement in the 
UK) captures something of the spirit of recovery, which 
we endorse – that it is, or should be:
• an individual process or journey rather than a pre-
determined destination
• built on hope, in order to sustain motivation and 
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support expectations of an individually fulfilled life
• about enabling people to gain a sense of control 
over their own problems, the services they 
receive, and their lives
• helping people to find opportunities to participate 
in wider society
• culturally appropriate.
2.8 One approach to understanding how 
recovery might be achieved is to focus on the concept 
of ‘recovery capital’, which the 2010 national drugs 
strategy defines as: 
 “the resources necessary to start, and   
 sustain recovery from drug and alcohol  
 dependence.” (HMG, 2010)
This focuses attention on what an individual needs to 
begin treatment and those aspects that are needed 
to maintain or build change. These needs may be 
different at the start of treatment, and when the 
individual is working to build or sustain their recovery. 
2.9 The strategy goes on to list four kinds of 
recovery capital, or resource (Best and Laudet, 2010):
• social: support from and obligations to family, 
partners, children, friends and peers
• physical: finances and safe accommodation
• human: skills, mental and physical health, a job
• cultural: values, beliefs and attitudes held by the 
individual.
2.10 Assessment and recovery care-planning 
should identify the key resources that will help support 
recovery for each individual, and help them build 
up and, hopefully, draw on such resources during 
their recovery journey. Although there is a research 
literature on some of these factors, in practice they will 
be different for each person. 
2.11 Treatment can provide opportunities for 
individuals to fulfil pro-recovery social roles, for 
example, as peer mentors or facilitators of SMART 
recovery groups, which in turn can inspire others in 
their recovery journeys.
2.12 The process by which individuals define their 
recovery choices may be enhanced by exposure to 
others also on a recovery journey. Mutual aid and peer 
support will be vital to ensure recovery is prominent 
in services and treatment systems. The mutual 
identification processes that happen through mutual 
aid and peer support are important. People need to 
identify with someone whose place in their recovery 
journey is not too remote to their own. Someone 
who has been abstinent for many years and in stable 
employment can be an important beacon of what can 
achieved in the long term but their experiences may 
be very different and mutual identification could be 
difficult. It is important that people can see the ‘hand 
and footholds’ at each stage of recovery through 
access to peers who are perhaps just a little further 
along the road to recovery than themselves.
2.13 There is a clear need for appropriate 
leadership across all providers of care in establishing 
explicit recovery-orientated assessment and care 
planning processes and in developing a more visible 
and overt recovery culture in services and across the 
systems of care.
2.14 An increasing number of people with past 
or current heroin dependence have intractable mental 
health or physical health problems. Some represent a 
complex medical problem requiring multidisciplinary 
coordination of care.
2.15 It is also important that treatment is 
delivered within clear and accountable clinical 
governance structures. Adequate supervision is a key 
component of this. It is particularly important that 
supervisors have the appropriate competences to 
supervise all the techniques or interventions being 
used by the practitioners they are supervising.
3 ASSESSMENT AND RECOVERY CARE 
PLANNING: PLAN, REVIEW, OPTIMISE
3.1 Introduction
3.1.1 Vital elements in an effective journey of 
treatment and recovery are:
• properly assessing and regularly reviewing an 
individual’s needs
• planning treatment to respond to these needs as 
they change during treatment
• optimising or adapting treatment interventions 
to respond to failure to benefit or to capitalise on 
windows of opportunities for faster recovery.
3.1.2 Done well, assessment, recovery care 
planning and review are more than exercises in form 
completion. As well as gathering vital information, 
assessing risk and informing the professional’s 
formulation, assessment can be an important 
therapeutic process in its own right. It can give people 
in treatment objective feedback on their situation 
and help them gain a different perspective or a more 
objective view of their lives – effectively a process of 
self-assessment and self-evaluation of their situation. 
This shared or joint assessment can then act as a 
platform on which to review and develop goals, and 
from which a recovery-focused care plan is agreed 
collaboratively. This process is likely to be of most 
therapeutic value if the resultant plan is going to be 
meaningful to individuals and owned by them. The 
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use of first-person statements and the person’s own 
words may help facilitate this ownership but, most 
fundamentally, the process should be a detailed and 
collaborative exploration of resources, goals, strategies, 
options, benefits and risks. These useful processes 
can set out the framework for further recovery care-
planning and review.
3.2 Assessment
3.2.1 There needs to be an initial, as well as an 
ongoing, process of comprehensive assessment for 
recovery that helps to underpin the core process of 
recovery care planning. Assessment for recovery aims 
to deliver an informed understanding of the person’s 
wishes, substance use, and the severity and complexity 
of clinical and other problems; and it needs to identify 
their strengths and any key obstacles to their recovery.
3.2.2 The assessment process needs to help 
individuals consider their current and potential future 
‘recovery capital’. This will include personal skills, 
availability of safe accommodation, presence of 
supportive relationships, current levels of personal 
responsibility, engagement with a supportive local 
community, and positive participation in wider society.
3.2.3 The visibility of those in recovery and 
exposure to the varied pathways of recovery are likely 
to be key elements of a truly comprehensive and 
collaborative assessment process. At initial assessment, 
the attention of many people coming into treatment 
will be on relieving acute distress or addressing urgent 
issues, and services may be concerned to minimise 
acute health risks such as overdose. So in many cases, 
initial stabilisation on OST will be a key priority as an 
early step to recovery. For others, active support for 
detoxification, followed by relapse prevention, may 
be appropriate. However, assessment and recovery 
care-planning is an ongoing process and, once initially 
stabilised on OST, collaborative and active care-
planning (e.g. using mapping tools and motivational 
approaches) to consider options across a wide range 
of personal recovery goals will be an important part 
of a recovery-orientated culture. For people to make 
informed choices through the assessment process, they 
need information and advice. As well as promoting 
clear pathways to recovery and abstinence, it is vital 
the nature of dependence is discussed and any risks of 
treatment and moving to abstinence are made clear. 
For collaborative recovery care-planning, people need 
balanced advice based on evidence, so they can weigh 
up their preferences and options in an informed way.
 Mental health
3.2.4 Drug treatment services need to be able to 
screen, assess and identify treatment need for mental 
health problems. Individuals with severe problems 
should have “high quality, patient-focused care”, 
delivered though close collaboration with mental health 
services (DH, 2002; DH & devolved administrations, 
2007). Mental health services normally lead the care 
for these people, with drug services providing guidance 
and support on managing dependence. This may 
include joint-working arrangements.
3.2.5 Drug treatment services need some ability 
to treat people with mild to moderate co-morbidity as 
the two conditions often share a common cause, or 
may require concurrent or sequential interventions for 
treatment to be most effective.
3.2.6 Up to 70% of the drug treatment population 
have been reported to have common mental health 
problems such as anxiety disorders (Weaver et al., 
2004).  IAPT services have been developed to work 
with depression and some anxiety disorders and can 
address the need in the drug treatment population, 
particularly for those stable on OST. IAPT services 
do not necessarily have the expertise to work with 
complex cases of trauma or with those who have not 
stabilised sufficiently on OST. Drug treatment services 
will need to be able to provide suitable support to 
people with such complex presentations.
 Physical health
3.2.7 For some people – and especially as the 
treatment population ages – physical health problems 
may be a persistent barrier to recovery. Drug treatment 
services need to be able to assess and identify 
treatment need for such problems, and work closely 
with healthcare providers to treat physical diseases that 
may be affecting multiple systems in the body. 
3.2.8 The provision and organisation of physical 
(as well as mental) healthcare for those in drug 
treatment needs to reflect the problems of access 
and stigmatisation commonly faced by drug users. 
Support may be needed for them to effectively 
use health and care services, including through 
proactive communication and advocacy, and – when 
appropriate – through direct provision of care within 
drug treatment services. Primary health care services 
can play a pivotal role in providing for the physical 
health needs of drug users but may need support 
from drug services.
3.3 Recovery care planning
3.3.1 A collaborative recovery care planning 
process should be able to identify preferred options 
from an attractive and flexible menu through which 
process someone in treatment can be helped to 
define their intended recovery journey. Recovery care 
planning will identify practical and staged actions that 
can promote progression to recovery. Individualised 
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recovery care plans for those receiving substitution 
treatments should not differ in any substantial way 
from those pursuing abstinence-based pathways.
3.3.2 It is important that recovery care-planning 
reflects and responds to the ambitions of service users, 
and gives them space, time and support to make 
meaningful decisions about their futures. Some people 
may have ambitions, or request related interventions, 
that are not currently achievable or clinically 
appropriate because of suitability, risk factors or 
contraindications. It is important that individuals do not 
experience these difficulties as a professional blocking 
their progress. Focus should normally be turned to 
developing plans, with realistic steps or milestones, that 
manage the risk or suitability issues appropriately while 
clearly maintaining or supporting a reframing of the 
original ambition and momentum.
3.3.3 An individual’s activity while in a treatment 
programme needs to be understood in relation to the 
phase of treatment they are in, the next phase to be 
attained, and the full context of a recovery journey that 
engages with and is supported by wider community 
structures. Section 4 describes this in detail.
3.4 Review and optimise
3.4.1 Good practice and care planning guidance 
(NTA, 2006) stress the importance of regular 
review. Reviewing the recovery care plan provides 
the opportunity to measure progress, evaluate the 
progress towards goals, including the impact of 
interventions, and set new goals that move individuals 
along their recovery journey. Measuring treatment 
benefit and progress is an integral part of this process.
 Measuring treatment benefit
3.4.2 There is robust evidence showing that OST 
can significantly improve outcomes for most opioid 
dependent people. Treatment can reduce symptoms 
of dependence, and being in treatment can help 
to reduce associated difficulties. However, more 
improvement in a broader range of domains is needed 
if someone is to fully recover. Many of these are 
covered by the term ‘recovery capital’ described earlier.
3.4.3 The ability to measure an individual’s recovery 
capital and its accumulation during treatment, using a 
set of agreed outcomes that represent change during 
drug treatment, and to demonstrate to an individual 
their specific improvements (or deteriorations) in 
treatment can help to:
• make effective decisions on which areas to 
target with adapted or optimised treatment 
interventions
• support the person’s confidence in their recovery 
and so support further progress in treatment.
3.4.4 The Treatment Outcomes Profile (TOP) is the 
national clinical instrument for monitoring outcomes 
in drug treatment. The TOP is now embedded in the 
treatment system and offers a core set of outcome 
measures to assess OST benefit.
3.4.5 While the TOP does measure some elements 
of recovery, additional measures of recovery capital 
are likely to be needed to present a better picture of 
recovery. Although some of these additional aspects 
of recovery may be difficult to observe or measure 
directly, they can be adequately represented by 
observable variables, such as the subjective rating of 
quality of life already used in the TOP. This approach is 
common in other areas of medicine.
3.4.6 Additional measures of recovery capital 
might cover, for example, change motivation and 
engagement, the support available to someone from 
their family and social network, skills and participation, 
and the environment in which they are living.
3.4.7 A core recovery measure for OST would 
be the extent to which the person in treatment is 
experiencing reductions in the psychological aspects 
of dependence, such as the desire or compulsion to 
take heroin, difficulties in controlling heroin use, and 
time devoted to obtaining or taking the drug or to 
recovering from its effects. There are standardised 
clinical interviews for the assessment of dependence 
(e.g. Composite International Diagnostic Interview 
(CIDI)) and validated clinical instruments for assessment 
of withdrawal (e.g. Subjective Opioid Withdrawal Scale 
(SOWS)), from which measures can be drawn.
3.4.8 Self-reported drug use or abstinence, such as 
measured in the TOP, is an important part of ongoing 
assessment of treatment benefit but testing biological 
samples for evidence of recent drug use can also be 
useful and sometimes vital. If people in treatment 
understand that drug tests will be requested at key 
points, the accuracy of self-reported abstinence is likely 
to be improved. Testing can also be used as another 
tool of the review and adaptation process but only if 
clinicians understand (and explain) how, why and what 
they are testing and how they will use the results – and 
understand the limitations of testing (see, for example, 
Goldstein & Brown, 2003). Drug testing during 
treatment is used to confirm treatment compliance 
(that someone is taking prescribed medication as 
directed) and as an indicator of progress in treatment 
– confirming abstinence or monitoring any continued 
drug use, including to support a drug-specific 
treatment intervention (e.g. as part of a psychosocial 
intervention like contingency management). Because 
of the risks of continued illicit opiate use for those 
on OST, a positive test result should lead to a careful 
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review of progress and the care plan, and of the need 
for increased treatment support or enhanced safety 
measures. A negative test result can be used to support 
and encourage someone in their continued progress.
3.4.9 Other measures of benefit and improvement 
beyond those recorded in the TOP might cover 
finances, relationships, risk and safeguarding issues.
3.4.10 The importance of these measures is not 
the tool used to collect them but the ways in which 
the information they provide is used meaningfully in 
a clinical setting with an individual and to optimise or 
adapt the treatment offered.
 Optimising and adapting treatment
3.4.11 If little or no improvement results from the 
current treatment interventions they may need to be 
adapted then reviewed again. This can help ensure 
treatment remains dynamic and responsive to need. 
Identifying ‘little or no improvement’ is important but 
must take into account continued harm reduction 
benefits and the prevention of deterioration.
3.4.12 It is important that treatment can be 
adapted or optimised within the same intensity ‘layer’ 
of treatment (see section 4). Service and treatment 
systems need a ‘breadth’ of interventions and a range 
of modifications they can make to these interventions 
to allow treatment to be adapted before its intensity is 
substantially stepped-up. A narrow, one-dimensional 
model of stepped care is not desirable as people could 
be escalated through it too quickly, deriving no benefit, 
when benefit could have been derived if the current 
level of treatment were adapted or modified.
4 THE PHASING AND LAYERING OF 
INTERVENTIONS
4.1 Introduction
4.1.1 This component of the report focuses on 
how opioid substitution treatment can be delivered in 
a dynamic way which does not allow people to drift 
into long-term maintenance prescribing without effort 
being made to promote their recovery.
4.1.2 It proposes structuring packages of care in 
two main ways:
• firstly, by ‘phasing’ or sequencing care in a 
progressive and dynamic recovery journey that 
delivers different interventions as appropriate at 
different stages
• secondly, by ‘layering’ in different intensities, 
deployed according to need, choice, efficacy and 
progress towards recovery.
4.1.3 It also outlines a set of principles, or 
components of good practice, which should underpin 
the approach. These principles are to ensure the 
approach is dynamic and personalised, safe and 
ethical. They should also, if adhered to, minimise the 
likelihood of any unwanted, unintended consequences 
being generated by the approach. 
4.1.4 Interventions and packages of care need 
to provide the flexibility to respond to individuals’ 
different rates or directions of movement, at different 
times in their recovery journey. 
4.1.5 The design of services and of practice needs 
to provide for recovery pathways that include opioid 
substitution treatment and abstinence, and for moving 
from one to the other as goals and recovery capital 
change. Regardless of the pathway and its duration, 
people in treatment can – and should be supported to 
– achieve substantial recovery goals.
4.2 Phasing and layering
4.2.1 Phasing of interventions through care 
pathways, treatment phases or stages is already 
used in many substance misuse services. Layering 
interventions or packages of care in a stepped care 
approach is also used in some substance misuse 
services, as well as in mental health care and in 
dedicated psychological therapy services. Care is often 
phased and layered on a case-by-case basis through 
independent clinical and/or managerial decisions. A 
more planned approach to service or treatment system 
design can assist in meeting the full range of need, 
which changes during a recovery journey. It can also 
assist in developing the competence of staff to meet 
this range of need in a more planned and strategic 
way. Furthermore different intensities of treatment 
support a rational and systematic approach to 
managing limited resources.
4.2.2 The phasing of interventions for those on 
OST could potentially allow for the more precise 
targeting of interventions. It could also follow that 
measurement is designed to measure progress 
through the phases and its outputs used as a basis to 
plan interventions that promote movement through 
the phases. The phases suggested here are conceptual 
and this may lead to problems of definition and in 
locating people in a particular phase, but they are only 
a suggestion to be used when it is useful to do so. The 
aim is to cluster interventions into phases to support 
their sequenced deployment.
4.2.3 Change can often be a cyclical and iterative 
process and, in contrast, the phases may appear to be 
strictly linear. This has a greater potential to engender 
movement, a sense of clear goals and a recovery-
orientated direction of travel. But clinical judgment 
and person-centred case management will be needed 
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to mitigate the risks inherent in a linear model: of only 
starting people at the beginning, driving them through 
before they are ready, and not allowing them to slip 
back to an earlier phase if they lapse, relapse or fail to 
benefit from treatment. Non-linear movement through 
phases, crises, fluctuations in motivation and ‘dips’ in 
and out treatment, will all need to be considered in 
the application of any phased approach.
4.2.4 What follows is a suggested approach to 
phasing and layering treatment. It is not intended as 
a rigid blueprint but rather as an illustration of the 
approach, to aid the development of local solutions. It 
consists of four phases of treatment: engagement and 
stabilisation, preparation for change, active change, 
and completion. It also consists of three layers of 
intensity: standard, enhanced and intensive: 
4.2.5 An example of how a treatment system 
or packages of care could be configured using this 
approach is included in table A (p19). Core keyworking 
interventions, such as harm reduction, assessment, 
care planning, referral and advocacy are listed in table 
B. They should be available as a standard and core 
component throughout any treatment journey.
 Engagement and stabilisation
4.2.6 At the beginning of treatment, people 
may not have decided to become immediately 
abstinent and may not have agreed their level of 
need and the full package of care. There is also a risk 
of early treatment drop-out. The engagement and 
stabilisation phase seeks to engage people in their 
own treatment and, if they drop out, bring them 
back in quickly. First impressions are important and 
the service will want to make it quick and easy for 
people to be assessed, start to receive treatment and 
address their presenting concerns, such as benefits or 
a forthcoming court appearance. Interventions seek to 
develop the therapeutic relationship and establish the 
components of keyworking designed to reduce harm, 
involve individuals in their treatment and help them 
navigate through their treatment journey. Important 
components of standard intensity care during this 
phase are: dose titration and optimisation; drug 
testing; and proactive and facilitated referral to mutual 
aid and low intensity psychosocial interventions. If 
such a package of care does not achieve the desired 
effect, the intensity can be increased to an enhanced 
level and utilise more formal motivational interviewing, 
contingency management and assertive outreach. 
Finally, if the initial goals of this phase are not achieved 
the intensive option of inpatient assessment and 
stabilisation could be considered based on clinical 
need.
 Preparation for change
4.2.7 This phase includes interventions that seek to 
refine treatment goals and prepare people for change. 
For some, with high levels of recovery or social 
capital, this phase could be very short, for others it 
will be more complex and take longer. After the initial 
engagement and stabilisation phase, some will opt for 
a period of OST maintenance (perhaps expressing an 
intention to come off OST in the future). Interventions 
designed to build their motivation should be utilised, 
strategically amplifying any dissonance, focussing on 
strengths, building self-efficacy and self-esteem and 
using any contingencies as appropriate. Others will 
present with or develop more motivation for change, 
insight and/or recovery or social capital. For this group, 
interventions focussed on preparation for the next 
phase will be appropriate. Both of these packages 
could be offered at three layers of intensity: standard, 
enhanced or intensive, according to the person’s level 
of stability and ambition:
• standard care for those stable on OST and 
wanting minimal other interventions but still 
including regular review and prompts for change
• enhanced care for those with limited initial 
motivation, perhaps with particular social needs 
(such as stable housing), or those with high level 
of motivation, insight or recovery capital who will 
benefit from more active and more structured 
interventions and peer support
• intensive care for those who fail to derive 
substantial benefit from enhanced care, or who 
are not stable enough to engage.
4.2.8 In some cases, if people do not respond to 
enhanced and intensive care (they could be showing 
partial benefit but care plan goals are not being wholly 
achieved) it may be appropriate to step back down to 
a lower level of care.
 PHASES
LAYERS
ENGAGEMENT AND 
STABILISATION
PREPARATION FOR 
CHANGE ACTIVE CHANGE COMPLETION
STANDARD 
TREATMENT
Packages of 
interventions
Packages of 
interventions
Packages of 
interventions
Packages of 
interventions
ENHANCED 
TREATMENT
Packages of 
interventions
Packages of 
interventions
Packages of 
interventions
Packages of 
interventions
INTENSIVE 
TREATMENT
Packages of 
interventions
Packages of 
interventions
Packages of 
interventions
Packages of 
interventions
THE TREATMENT JOURNEY
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4.2.9 It is important to differentiate standard 
maintenance on OST in a recovery-orientated system 
of care from the criticism that some people have been 
‘parked’ on methadone. Regular recovery care plan 
reviews and the recovery-orientated culture, enhanced 
visibility and facilitated access to mutual aid, and a 
more overt collaborative approach to care planning 
should ensure nobody stays on OST for any longer than 
appropriate. However, it is equally vital that resources 
are used efficiently and are not wasted in providing 
interventions that are not likely to be successful.
 Active change
4.2.10 The focus in this phase is on interventions 
that seek to initiate and maintain change, especially 
detoxification, and social and rehabilitative options. For 
some this phase could come quickly; others may spend 
longer in the ‘Preparation for change’ phase. Standard 
packages could include community detoxification, 
keyworking and low intensity psychosocial 
interventions. Enhanced packages could include more 
formal psychosocial interventions. Intensive packages 
would include in-patient and medically-monitored 
residential detoxification, residential rehabilitation and 
structured community rehabilitation programmes. 
Proactive and supported engagement with mutual aid 
and peer support should be a priority in this phase.
 Completion
4.2.11 This phase includes interventions that help 
people reflect on, prepare for and exit from formal 
treatment. NICE recommends: “Following successful 
opioid detoxification, and irrespective of the setting 
in which it was delivered, all service users should be 
offered continued treatment, support and monitoring 
designed to maintain abstinence. This should normally 
be for a period of at least 6 months.” (NICE, 2007a)
4.2.12 Aftercare planning and engagement in 
mutual aid should be prominent. The phase includes 
interventions that seek to strengthen community 
integration and further develop recovery capital. The 
components of care packages are similar to those 
in the active change phase, but ownership of plans 
and their fulfilment should be located firmly with the 
individual, a progression which should have started in 
the earlier phases. The addition of relapse prevention 
medications, such as naltrexone, could be considered.
It is important that the planning of treatment exit and 
post-treatment support start early, well before the end 
of structured treatment, and is detailed and realistic.
4.2.13 After someone has left treatment, services 
may want to provide recovery check-ups (see section 
5.7.3). Rapid access back into structured treatment 
should also be available, if needed.
4.3 Phasing treatment in prison
4.3.1 A particular combination of factors informs 
drug treatment approaches in prisons:
• a high concentration of drug users within the 
population (Stewart, 2008)
• a significant reduction in drug consumption 
during imprisonment (NOMS, 2009)
• a marked reduction in injecting drug use during 
imprisonment (but where it does occur, a higher 
incidence of sharing of needles and other 
equipment: Bellis et al., 1997)
• the high volume and frequency of movement of 
prisoners in treatment (one spell of custody can 
involve brief residency in four prisons: Marteau & 
Farrell, 2005)
• the high risk of overdose on release (Farrell & 
Marsden, 2005)
• a correlation between drug withdrawal and suicide 
in the first week of custody (Shaw et al., 2003)
• the high value of drugs relative to prisoners’ small 
incomes (DH & devolved administrations, 2007).
4.3.2 These factors mean it is appropriate to 
take a modified approach in which stabilisation is 
offered from the first night of custody, and extended 
prescribing is reviewed at least every three months (DH, 
2010). Unless there are clinical reasons to the contrary, 
individuals whose sentence exceeds 26 weeks are 
expected to work towards becoming drug free.
4.3.3 UK clinical guidelines (DH & devolved 
administrations, 2007; DH et al., 2006) currently 
recommend treatment options that address the clinical 
risks and opportunities that prisons afford:
First week of custody
• timely stabilisation for opioid withdrawal 
• enhanced observation for those in stimulant 
withdrawal
• timely stabilisation or reduction for alcohol and 
benzodiazepines.
Weeks that follow
• option of opioid maintenance or detoxification
• range of evidence-based interventions (Patel, 
2010)
• treatment reviews.
For sentences beyond six months
• opioid reduction (detoxification) where indicated 
(DH et al., 2006)
• range of evidence-based interventions
• treatment reviews.
Prior to release
• enhanced support (via mutual aid, peer 
mentoring, offender management)
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• naltrexone in accordance with NICE technology 
appraisal (NICE, 2007b)
• consideration of re-induction (DH & devolved 
administrations, 2007)
• continuation of treatment and support (Patel, 
2010).
4.4 Some key principles for delivering 
packages of care
4.4.1 The following principles, or components 
of good practice, should underpin the phasing 
and layering approach described above. These 
principles are to ensure the approach is dynamic and 
personalised but also safe and ethical. They should 
also, if adhered to, minimise the likelihood of the 
approach generating any unintended consequences. 
 The maintenance of adequate harm 
reduction interventions
4.4.2 OST has a substantial role in reducing 
harm and in preventing deterioration. Together 
with measures such as needle and syringe provision, 
OST has been responsible for the UK having one of 
the lowest rates in the world of HIV/AIDS among 
injecting drug users. Harm reduction interventions 
provide an underpinning of safety for all and should 
be appropriately embedded in all recovery pathways 
– they are included in the core keyworking activities 
undertaken in every phase of treatment (table B).
 Timescales 
4.4.3 Robust application of dynamic recovery care 
planning cycles should ensure that arbitrary timescales 
for interventions are not required to promote recovery. 
This allows for recognition of the evidence in relation 
to the length of drug using careers but also maintains 
a sense of dynamism or progress in the system. 
Local issues, such as access to housing, education, 
employment and training can also have a significant 
impact on timescales. 
4.4.4 It is also crucial to acknowledge that, 
while there is political and clinical consensus that 
treatment needs to support individuals to maximise 
their recovery, we do not yet have adequate evidence 
on the likely scale of impact from developing a 
more recovery-orientated culture around the use 
of OST. So, we cannot predict with any assurance 
the numbers likely to fall in each category described 
(phase or intensity), nor the greater proportion likely 
to achieve successful sustained abstinence. We will 
also need to monitor any possible negative impact on 
increased harms (such as overdoses and drug deaths). 
This is not least because some of the possible key 
factors that could affect positive recovery outcomes 
such as housing access and support for training 
and employment may vary widely in availability and 
impact. However, it is clear from current knowledge 
and experience that many of those on OST will need 
to be on it for several years.
 Psychosocial interventions
4.4.5 The enhanced level of intensity, defined 
in table A, contains a number of psychosocial 
interventions, all of which are in the 2007 Clinical 
Guidelines (DH & devolved administrations, 2007) 
and some of which are recommended as priorities for 
implementation because of their high-quality evidence 
by the NICE guideline on psychosocial interventions 
in drug misuse (NICE, 2007c). The interventions at 
this level require specialist training or reference to 
implementation and clinical governance frameworks 
developed for the needs of research trials rather than 
the delivery of clinical services. While these represent 
an aspirational standard, in day-to-day practice it 
may be neither feasible nor desirable to adhere 
rigidly to these protocols. However, these enhanced 
interventions have important elements that keyworkers 
can adopt and deliver in addition to their core duties. 
This may enhance the standard offer of treatment. For 
example, if collaborative review identified the need for 
more supportive social networks, if SBNT was available 
this could be utilised. Alternatively, low- intensity 
psychosocial interventions could focus on this area, 
using relevant techniques, such as mapping, to support 
someone to explore, develop and use social networks.
4.4.6 Adapting evidence-based interventions to 
the platform of keyworking requires clinical leadership 
and a clinical governance architecture (particularly 
supervision) to ensure critical ingredients are not so 
diluted they become meaningless. Within a robust 
clinical outcomes-driven framework, a key role of senior 
clinicians is to oversee this adaptation of psychosocial 
interventions in terms of overall programme design and 
the needs of people in treatment.
4.5 Residential and non-residential 
rehabilitation
4.5.1 Clinicians, and people in treatment, need to 
be aware of the range of options available for residential 
and non-residential rehabilitation, their benefits and 
how they might be used at different phases of the 
treatment journey. Collaborative recovery care planning 
needs to be based on a platform of informed choice.
4.5.2 It seems clear that, for some people, 
recovery is likely to be better supported in a service 
that provides a safe environment, daily structure, 
range of psychosocial interventions, higher intensity, 
accessible peer support, etc – all conducive to recovery.
4.5.3 Rehabilitative treatment has often been 
reserved until the later phases of an individual’s drug 
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use or treatment journey, and residential treatment 
reserved for those with no or unstable housing or for 
whom non-residential options have been unsuccessful. 
However, in line with the phasing and layering approach 
described in section 4.2, rehabilitation may be cost 
effective when used earlier for someone who is ready 
for active change and a higher intensity treatment.
4.5.4 Residential services are currently developing 
evidence, workforce competences and a means of 
categorising the broad range of available models.
4.6 Medications in different settings
4.6.1 There is further work to be done in examining 
the possibilities for existing and potential new 
medications to be used in a range of settings, including 
some where medication is currently little used. These 
potentials can be understood across a number of axes: 
the medications themselves, the points in a treatment 
journey where they might be appropriately used, and 
their stage of development or use.
4.6.2 Medications that we believe merit further 
attention are those that can contribute to:
• the prevention of co-morbidity, such as vaccines 
against blood-borne viruses
• replacing (if only temporarily) a drug on which 
someone has become dependent, including 
nicotine replacement therapies and existing or 
new formulations of opioid agonists
• the prevention of relapse to illicit drug use 
following a course of treatment, including 
different formulations of naltrexone and possible 
future vaccines
• the treatment of the complications and 
consequences of drug misuse, including hepatitis 
C treatment and naloxone.
4.6.3 All of these medications may be able to find 
appropriate uses at the following points in a treatment 
journey:
• before someone goes into a particular treatment 
setting
• during treatment in a particular setting
• immediately following a course of treatment
• in the longer term, following treatment.
4.6.4 The range of medications to be considered 
covers a wide range of stages of development and 
use, including those:
• that already exist, are available and whose use is 
widespread and familiar to clinicians
• that already exist and are available but whose 
take-up has not reflected their apparent promise
• that exist but that are largely unavailable perhaps 
because their use is still being developed, 
including in clinical trials
• new medications that can already be seen on the 
horizon of development.
4.6.5 One of the issues to be addressed in relation 
to these medications is settings in which their use is 
currently minimal or non-existent because the support 
they provide is considered to be against the very ethos 
of the setting or liable to cause problems of equity 
among the treatment population. An example might 
be the use of the relapse-preventing opioid antagonist, 
naltrexone, in some abstinent rehabilitation 
programmes. In this example, is a resident to whom 
a long-acting naltrexone formulation has been 
administered somehow going against the ethos – and 
the interests of other residents – of a programme that 
lays great store on (and expects of its other residents) 
strength of will and the ability to resist temptation in 
the absence of any medicinal support?
4.6.6 These are complex issues and another 
group of experts is considering them with a view to 
publishing a separate report that will complement ours.
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5 RECOVERY SUPPORT
5.1 Introduction
5.1.1 We have been clear about the importance 
of building on the ‘recovery capital’ someone needs 
in order to attain and sustain their recovery: their 
social, physical, human and cultural resources. Drug 
treatment services have only a part of play in this – it 
depends heavily on the contributions of other health 
and social care services, housing and employment, 
family, friends and peers, etc. But treatment’s part can, 
and for many should, be vital and substantial:
• initiating recovery with a clear rationale for 
interventions in the context of achieving self-
sustained recovery
• directly helping to build capital in those starting 
from a low base
• involving support networks in treatment through 
interventions such as family support and social 
behaviour network therapy
• referring to, and actively supporting, contact with 
other services and peer support group
• involving peers directly through models such as 
peer role-models and recovery coaching
• bridge-building with peer communities of support.
This section is focused on the ways treatment services 
can support, rather than directly contribute to, recovery.
5.2 Peer role-models and peer support
5.2.1 To promote recovery within local systems 
and services it must be visible, as an active process 
that is being undertaken and as a possibility that 
is understood through the experience of others. 
Peer-based recovery support is an effective means of 
communicating to people in treatment that ‘recovery 
is possible’. Making recovery visible – through peer 
role-models (including recovery champions, recovery 
coaches, networks of peer-based recovery support and 
mutual aid groups) will, for many, effectively improve 
understanding, heighten people’s treatment ambitions 
and motivate them to work towards recovery. 
5.2.2 A body of evidence suggests that self-help 
approaches, alone or in combination with a package 
of structured treatment, can help people to reduce 
or stop their drug use and sustain recovery. The 
National Institute for Health and Clinical Excellence 
(NICE) recognises the efficacy of self-help approaches, 
particularly those based on 12-step principles. NICE 
recommends that information about self-help groups 
should be routinely provided by drug treatment staff 
and that access to 12-step and other self-help groups 
should be facilitated by, for example, making initial 
contact, arranging travel and accompanying people to 
their first meeting). Well-developed networks of peer 
support will be effective in meeting the more general 
needs of those in treatment. They help to empower 
people to take greater responsibility for their lives and 
can result in reduced dependence on drug treatment 
services for general advice, information and support.
5.2.3  Ensuring pathways to recovery are visible 
can be a powerful feedback and motivating tool. The 
mutual identification processes that happen through 
mutual aid and/or peer support are important. It is also 
important that individuals can identify with someone 
whose place in their recovery journey is not too remote 
to their own. Someone who has been abstinent for 
many years and in stable employment can be a beacon 
of what can be achieved in the long term but their 
experiences may be different and mutual identification 
may be difficult. People should have access to peers 
who are perhaps just a little further along the road to 
recovery than themselves, who are easier to identify 
with and who can share common experiences. Some 
service user involvement, like gathering feedback, 
is another way of making recovery visible. Visible 
pathways can show people in treatment (and staff) 
the progress they have made in a treatment journey 
and the possible ways forward. Recovery communities 
and champions can be useful components to achieve 
this. Although recovery journeys are individual, they 
describe a common path with familiar landmarks 
such as: stability of use, stable accommodation, 
positive support networks, reduced medication, and 
detoxification. When services seek to increase the 
visibility of recovery they should not restrict themselves 
to the recovery examples associated with a reintegrated 
abstinent end state, but seek to make visible the ‘hand 
and footholds’ at each stage of recovery. Capturing 
recovery stories from people and displaying them in 
treatment services also makes recovery more visible.
5.2.4 To optimise the benefits of self-help 
approaches it will be crucial that local areas develop 
good relationships with existing local mutual aid 
networks and other peer-based recovery support 
groups and encourage the development of new local 
groups/services in the community and within the 
treatment population. A number of steps may be 
useful to encourage and support engagement:
• identify and appoint local strategic, therapeutic 
and community recovery champions:
– with the remit of understanding, developing 
and communicating a locally agreed narrative of 
recovery
– improve integration between drug treatment 
and peer support 
– develop links between drug treatment providers 
and key contacts within the various local mutual 
aid, peer support groups/services
– ensure that staff have access to appropriate 
information and training about the various 
mutual aid organisations
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• improve the visibility of recovery by:
– ensuring everyone has access to a recovery 
coach, or the opportunity to speak with people 
who are in recovery through local peer-support 
services
– inviting the Hospitals and Institutions (H&I) 
service post-holder of the various 12-step 
fellowships or appropriate representative of 
SMART recovery and other local groups to talk to 
people in treatment
• improve knowledge and understanding of peer 
support among staff and those in treatment by:
– staff attending open meetings, which anyone, 
including professionals, can attend as observers
– inviting Public Information (PI) service 
post-holders of 12-step fellowships to give 
presentations at team meetings to improve staff 
knowledge
– inviting H&I service post-holders to talk to 
people in treatment as above
• support the development of mutual aid and peer 
support meetings by:
– ensuring drug treatment premises are available 
for meetings
– working with mutual aid groups to time meetings 
to maximise attendance by those in treatment
• promote choice by:
– ensuring people in treatment have a range of 
peer-support options including 12-step, SMART 
Recovery and other local peer-support services
• facilitate access by:
– making initial contact on behalf of someone
– organising travel, where necessary 
– accompanying them to their first meeting
– taking time to explain what meetings can offer 
and how they operate, dispelling any myths or 
preconceptions
– organising for a member of the mutual aid 
group to meet with someone who is considering 
attending for the first time so they can explain 
what happens at a meeting, explore any concerns 
and establish a contact within the group.
5.3 Employment support
5.3.1 Work, paid or unpaid, can be a vital part of 
recovery, helping people to gain self-esteem and build 
their social identity. Routes into work during recovery 
can help to sustain gains made in treatment. There is 
also a wider benefit to society from reduced costs to 
the welfare system.
5.3.2 But drug users’ employability can be affected 
by physical and mental health problems, unstable 
accommodation, offending histories and limited skills 
or employment experience.
5.3.3 Employability may also be affected by the 
attitudes of employers and people in treatment to 
OST. It needs to be clear to both that, far from being 
a disability to working, OST can be the stabiliser that 
enables someone to work.
5.3.4 Treatment providers can raise the profile 
of employment as an integral part of the recovery 
pathway. Through their own services, local recovery 
communities or partnerships with others they can 
introduce people to work experience in ways that are 
flexible and appropriate to individuals’ needs.
5.3.5 Drug and alcohol treatment providers 
already discuss education, skills and employment-
related needs, and other aspects of social functioning, 
as part of the assessment process, and the person in 
treatment and their keyworker agree goals as part of 
the recovery care plan. It may be useful to identify and 
record specific information in relation to employment 
and benefits, such as whether the person is claiming 
JSA or ESA and has a Jobseeker’s Agreement or action 
plan agreed and, if so, what needs and goals have 
been agreed and whether they match those identified 
in the comprehensive assessment.
5.3.6 Treatment providers can facilitate closer 
working arrangements between people in treatment, 
Jobcentre Plus (JCP) and (when relevant) the Work 
Programme provider. Better information sharing and 
joint-working between JCP (and Work Programme 
providers) and treatment providers can help to identify 
individual employment, training and skills needs 
as early as possible during a recovery journey, so 
appropriate provision and funding can be put in place 
at the right time. It can also help ensure the Jobseeker’s 
Agreement and action plans reflect progress in 
treatment and that support is tailored and appropriate. 
Services can also help people comply with any benefit 
conditionality or required interaction with JCP services.
5.4 Family and social networks
5.4.1 Family and other social network support 
can be vital to recovery as they contribute to a 
person’s social recovery capital. The addition of just 
one abstinent person to a drinker’s social network 
increased the probability of abstinence in the next year 
by 27% (Litt et al., 2009).
5.4.2 NICE’s 2007 guide to psychosocial 
interventions recommends behavioural couples 
therapy or behavioural family interventions for those 
in close contact with a non-drug-misusing family 
member, carer or partner (NICE, 2007c).
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5.4.3 Other psychosocial interventions such as 
the Community Reinforcement Approach and Social 
Behaviour and Network Therapy may be useful to 
involve, or – where they do not already exist – build, 
social networks (DH & devolved administrations, 2007).
5.4.4 Families may also need support in their 
own right. They should – as appropriate – be offered 
assessment, guided self-help, information and advice, 
facilitated contact with support groups, and individual 
family meetings (NICE, 2007c). They may also benefit 
from manualised interventions such as the 5-Step 
Method (Copello et al., 2010). Some may benefit from 
a formal carers’ assessment.
5.4.5 Mutual aid groups have long provided 
social network support for recovering drug users. 
New recovery communities play an increasing role in 
providing similar, and sometimes extended, support.
5.5 Housing support
5.5.1 Housing – and access to it – is, perhaps, 
the recovery resource least open to influence by drug 
services. A lack of appropriate local housing stock 
may seriously hamper efforts to support recovery and 
there may be little if anything that drug services can 
do directly to improve the situation. However, drug 
treatment workers and their services can take a few 
steps to improve people’s ability to secure and retain 
accommodation conducive to recovery, for example:
• assess housing-related need at entry to treatment 
and review it regularly. This is not just about 
housing status but about the skills necessary to 
maintain independent living
• optimise treatment to improve someone’s stability 
and ability to satisfy a landlord of their ability to 
maintain a tenancy
• provide advice, information and advocacy to 
ensure people in treatment are being paid 
appropriate benefits
• provide training and support (or access to them) 
in the skills needed to maintain a household 
and tenancy, including financial and debt 
management to ensure rent is paid
• work with people to improve chances of 
employment, which can help with housing
• provide, often in partnership with others, second-
stage or other supported accommodation
• provide housing support.
5.5.2 Beyond this work with individuals, drug 
services will also want to work, directly and through 
local drug partnerships, with local housing planners 
and providers to ensure they understand the benefit 
to individuals and the community of stable housing 
for drug users, that local need for housing has been 
assessed, and that appropriate housing stock to meet 
these needs is made available to people in treatment 
and recovery.
5.5.3 There is a balance to be struck between 
providing independent housing to someone to 
support their recovery and providing it too early in 
their recovery journey. The pressure of maintaining a 
tenancy may increase the risk of relapse and of losing 
the housing.
5.6 Improving well-being
5.6.1 There is good evidence the general 
population can secure improvements in mental health 
and well-being through the ‘five ways to well-being’ 
(Aked, Marks, et al., 2008):
• Connect. With the people around you. With 
family, friends, colleagues and neighbours. At 
home, work, school or in your local community. 
Think of these as the cornerstones of your life 
and invest time in developing them. Building 
these connections will support and enrich you 
every day
• Be active. Go for a walk or run. Step outside. 
Cycle. Play a game. Garden. Dance. Exercising 
makes you feel good. Most importantly, discover 
a physical activity you enjoy; one that suits your 
level of mobility and fitness
• Take notice. Be curious. Catch sight of the 
beautiful. Remark on the unusual. Notice the 
changing seasons. Savour the moment, whether 
you are on a train, eating lunch or talking to 
friends. Be aware of the world around you 
and what you are feeling. Reflecting on your 
experiences will help you appreciate what matters 
to you
• Keep learning. Try something new. Rediscover 
an old interest. Sign up for that course. Take 
on a different responsibility at work. Fix a bike. 
Learn to play an instrument or how to cook your 
favourite food. Set a challenge you will enjoy 
achieving. Learning new things will make you 
more confident, as well as being fun to do
• Give. Do something nice for a friend, or a 
stranger. Thank someone. Smile. Volunteer your 
time. Join a community group. Look out, as 
well as in. Seeing yourself, and your happiness, 
linked to the wider community can be incredibly 
rewarding and will create connections with the 
people around you.
5.6.2 It is not known whether the evidence 
that supports the five ways to well-being can be 
extrapolated to the treatment population, many 
of whom may have multiple, complex needs that 
overshadow the five ways. However, as these needs 
are addressed and they progress in their recovery 
journey, it seems likely that the five ways to well-being 
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will become more pertinent to people in treatment, 
and that treatment services and recovery communities 
can, and should, provide ways to support them.
5.6.3 For example, some treatment services 
provide access to sport and exercise, and to learning. 
Recovery communities create connections for people 
and let them give back in exchange for the support 
they have received.
5.7 Post-treatment support
5.7.1 Drug-related aftercare may typically include 
educational, psychosocial, and pharmacological 
interventions or a combination of these interventions. 
For example, somebody recovering from heroin 
dependence may benefit from pharmacological 
interventions like naltrexone, perhaps combined 
with a psychosocial intervention like contingency 
management (NICE, 2007c). 
5.7.2 The level and intensity of ongoing recovery 
support that might be offered to someone following 
treatment will differ depending on their recovery 
capital. However, some key components may include:
• access to mutual-aid groups or peer support
• support from a recovery coach
• engagement with housing, employment and 
educational support
• family and parenting support.
5.7.3 Local treatment systems may also want to 
provide recovery check-ups: regular phone calls to (or 
other contact with) people who have left structured 
treatment. Long-term monitoring through regular 
check-ups and early re-intervention can facilitate early 
detection of relapse, reduce the time to treatment 
re-entry and improve long-term outcomes (Scott and 
Dennis, 2009). Recovery check-ups are done more 
frequently when someone has first left treatment (at 
least once a quarter) and then tail off (to no less than 
once a year). They may continue for as long as five 
years. However, the duration and intensity of check-
ups for a particular individual will be based on their 
problem severity and recovery capital. A recovery 
check-up provides an opportunity to:
• assess how the person’s recovery is progressing
• provide feedback and support
• provide rapid access back into structured 
treatment, if needed
Scott and Dennis (2003) provide more detailed 
information in their model for recovery management 
checkups.
5.7.4 A rapid and clear route back into structured 
treatment is vital in case someone experiences 
difficulties in maintaining their recovery (DH & devolved 
administrations, 2007). Local treatment systems 
should ensure that referral pathways are in place, and 
treatment services have a rapid re-entry option.
6 THE EVIDENCE ON OST AND ITS 
EFFECTIVENESS
6.1 Introduction
6.1.1 Our evidence review had two goals:
• to summarise and interpret the evidence for OST
• to identify, from the evidence, those elements of 
OST that most obviously ensure its effectiveness.
The sections below summarise our principal findings 
for each of these goals, but the detail is in appendix C.
6.1.2 We also considered what proportion of those 
who become dependent on heroin might be expected 
to recover, or at least become abstinent from the drug, 
which is the measure usually used in the research.
6.1.3 The available evidence on specific aspects of 
OST is often limited and may come from only a few, 
often small-scale, studies in other countries. England’s 
National Drug Treatment Monitoring System (NDTMS) 
is increasingly able to supplement these findings 
with its population-scale reports on the features and 
outcomes of treatment in this country.
6.1.4 But the published evidence is clear that, 
at aggregated population levels, time-limited OST 
is not effective; that coming off OST can lead to 
greater risks of relapse, BBVs and overdose; and that 
treatment orientated to rapid abstinence produces 
worse outcomes than treatment initially orientated to 
maintenance (Ball and Ross, 1991). However, an initial 
orientation to maintenance does not mean people 
should be discouraged from seeking to withdraw 
from treatment if they are doing well, and have or 
can gain sufficient recovery capital to sustain long-
term abstinence. People who achieve good social 
reintegration, particularly employment, are more likely 
to leave treatment without relapse (Milby, 1988). 
Initially orientating OST to maintenance allows people 
the time, space and platform to make meaningful 
choices. This process is best supported by ambitious, 
integrated, diverse and targeted interventions and 
other support. It is not supported by limiting choice 
through unilaterally curtailing or time limiting OST.
6.1.5 The task of recovery orientated drug 
treatment is to do all it can to help people do well, to 
boost their recovery capital and ensure they have the 
resources necessary to protect against relapse.
6.2 The effectiveness of OST
6.2.1 The evidence is good that OST:
• prevents people dropping out of treatment –. 
however, in itself, preventing drop-out is only 
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a predictor of benefit, not an end in itself. A 
programme focused only on retaining people 
lacks an adequate direction for treatment. This is 
the critical role of the recovery agenda in shaping 
OST. It sets out treatment objectives that provide 
direction and structure for people in treatment 
and clinicians
• suppresses illicit use of heroin – three large 
studies from different countries provide 
surprisingly consistent results. Heroin use was 
reduced, with only 25-35% of users reporting 
continuing heroin use three to five years after 
beginning their index treatment
• reduces crime – OST reduces involvement in crime 
among heroin users participating in treatment 
(Lind et al., 2005) and the expansion of treatment 
is associated with reduced property crime in the 
community (Moffatt et al., 2005). OST given prior 
to release from prison can reduce re-offending 
(Gordon et al., 2008; Dolan et al., 2005)
• reduces the risk of BBV transmission – coupled 
with the availability of needle and syringe 
programmes (NSP), OST reduces the risk of BBV 
transmission (NICE, 2009), including in prisons 
(Singleton et al., 1998)
• reduces risk of death – OST reduces the risk 
of death among heroin users participating 
in treatment (Clausen et al., 2008), and the 
expansion of OST (specifically buprenorphine) 
reduced the overall rate of opioid overdose 
deaths in the community (Romelsjö, 2010). OST 
in prison may also reduce self-inflicted death 
in the first 28 days of imprisonment (Marteau, 
Palmer & Stoever 2010) and pre-release OST can 
reduce the high risk of fatal overdose during the 
first month of liberty (Gordon et al., 2008; Dolan 
et al., 2005).
6.2.2 The evidence is less persuasive that OST:
• suppresses other drug use – results of large, 
observational studies suggest OST is minimally 
effective at suppressing use of drugs other than 
heroin
• promotes abstinence from all drugs, including – 
in the longer term, OST medications themselves
• improves physical and mental health – there is 
relatively little data on which to assess health 
outcomes (other than reduced risk of overdose 
and BBV) but, broadly, the evidence suggests 
rapid and substantial improvements on treatment 
entry, which may or may not be maintained or 
further improved
• improves social reintegration of marginalised 
heroin users – there is little quantitative data 
available on which to assess the extent to 
which people in OST are able to achieve social 
reintegration. 
6.2.3 The evidence also alerts us to the risks of 
prescribing OST, especially to people who may find it 
difficult not to take illicit drugs or drink to excess:
• mortality in the first few weeks of OST is 
significantly elevated, as it is in the weeks after 
leaving treatment (Cornish et al., 2010)
• induction onto methadone is hazardous and 
needs to be undertaken with care, with the 
person taking the medication understanding the 
risks involved (DH & devolved administrations, 
2007).
6.3 The components of effective OST
6.3.1 The evidence also indicates the treatment 
components more likely to deliver the benefits 
described above. They include:
• engaged, stable clinical leadership that provides 
clear goals and maintains the cohesion, focus and 
engagement of clinicians to sustain a therapeutic 
milieu in which to optimise recovery (Ball and 
Ross, 1991; Magura et al., 1999)
• an organisation and staff able to support and 
sustain change, including motivated staff with 
appropriate qualifications, confidence in their 
skills, and a proportion in recovery themselves 
(CSAT, 2009), effectively supervised by competent 
clinicians and managers (Miller et al., 1995; 
Stitzer and Kellogg, 2008)
• longer retention in OST (Simpson & Sells, 1982; 
Zhang et al., 2003; Cornish et al., 2010) and an 
initial orientation to maintenance for up to one 
year or more but with people encouraged to 
move on from treatment if they are doing well, 
and have or can gain sufficient recovery capital to 
sustain long-term abstinence (Milby, 1988)
• staff who believe in the treatment they are 
delivering, have a genuine interest and concern 
for the people they work with and respond 
empathically towards them (Rogers, 1957), who 
treat them with respect and dignity that allows 
them to develop a different image of themselves, 
and who have a belief in their capacity to change, 
and a sense of their role in fostering that change 
(Dole & Nyswander, 1973)
• a structured programme focused on recovery that 
sets out treatment goals for OST that provide 
direction and structure for people in treatment 
and clinicians (Moos, 2003) 
• a range and quality of psychosocial interventions 
that enable emotional, psychological, and 
social well-being. NICE’s 2007 review found 
good evidence for contingency management 
supporting longer continuous periods of 
abstinence during and after treatment. 
Behavioural couples therapy and family-based 
interventions were also associated with reductions 
in illicit drug use. CBT for addressing common 
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mental health problems was also recommended. 
Active referral to and facilitation of contact 
with self-help (12-step) groups produced better 
sustained attendance at groups (NICE, 2007c)
• a sufficient dose of OST to prevent withdrawals 
or, if needed, high enough to increase tolerance 
and attenuate any response to injected heroin. 
And the provision of alternative medications or 
dosing schedules for those who experience low-
grade withdrawal symptoms in the latter half of 
the dosing interval and continue to use heroin 
despite receiving adequate doses of methadone
• availability of a range of OST medications, and 
of supervised consumption, to tailor treatment 
to individual needs, incentivise participation and 
maximise retention in structured treatment, and 
ensure safety
• links to recovery-orientated community 
organisations outside of treatment to enhance 
social reintegration, especially though employment
• continued treatment, support and monitoring 
designed to maintain abstinence for a period of 
at least six months following detoxification (NICE, 
2007a)
• availability of naltrexone, with adequate 
supervision and a programme of care, as a 
treatment option for detoxified people highly 
motivated to remain in an abstinence programme 
(NICE, 2007c)
6.3.2 While this summarises what the evidence 
says about the components of effective OST, it says 
little about whether these or other components 
can lead to long-term recovery. In particular, the 
evidence is mixed in demonstrating the effectiveness 
of psychosocial interventions on improving the target 
outcomes of OST. However, it seems clear that if we 
are to help people recover rather than just protect 
them from the harm of illicit drug use, we need staff 
who are competent in building relationships, able to 
provide structure and review, and with the flexibility 
to review progress and provide personalised access to 
a range of interventions. These are all the province of 
psychosocial interventions.
6.4 Beyond the limitations of OST
6.4.1 The critical limitation of OST, and all forms 
of treatment, is that individuals need long-term social 
support and personal psychological resources to sustain 
recovery. Formal treatment can be a powerful factor 
in building social support and psychological resources 
to facilitate positive change, but on its own it typically 
does not have a lasting influence (Moos, 2003).
6.4.2 People need alternative rewards in their lives 
if they are to recover from drug dependence. The 
rewards of everyday life (for most people, a stable, 
intimate relationship, fulfilling work, and family life) 
are less accessible for people marginalised, and who 
lack interpersonal and vocational skills, entrenched by 
drug dependence
6.4.3 There is some evidence that participation 
in training and employment can be fostered by 
treatment. One early randomised trial comparing 
treatment with methadone to drug-free treatment 
included intensive vocational retraining, and 
limit-setting in relation to continued drug use. 
It demonstrated that OST, in a package with 
other measures, can dramatically improve social 
reintegration (Gunne & Grondbladh, 1981)
6.4.4 OST, like all forms of treatment for drug 
dependence, relies on motivation: willingness 
to accept treatment, and more importantly, the 
willingness, personal resources and social opportunities 
to take advantage of the respite from dependence to 
make steps towards sustained recovery. All of these 
factors can be enhanced by service and staff factors, 
and psychosocial interventions described earlier
6.4.5 A focus on recovery can enhance the 
effectiveness of treatment through clarity of 
therapeutic goals. Every clinical interaction is most 
useful if focused on specific performance goals 
related to the person’s circumstances (Moos, 2003). 
Such focus can be enhanced by specific treatment 
protocols, and implementation of treatment 
concordant with treatment guidelines can enhance 
outcomes (Barnett et al., 2010).
6.5 How many people dependent on heroin 
become abstinent?
6.5.1 It is important to develop an understanding 
of how many people might be expected to recover 
from drug – and especially heroin – dependence but 
recovery is difficult to measure objectively. Researchers 
have therefore usually measured only remission from 
heroin dependence, actualised as abstinence over a 
defined period of time.
6.5.2 It is first useful, though, to provide some 
comparison with work done on recovery from 
alcohol and tobacco dependence. Vaillant’s follow-
up study of 174 men previously diagnosed with 
alcohol dependence showed that among 91 surviving 
participants at age 70, 53% had been stably abstinent 
for at least three years, 5% were drinking with no 
problems, and 42% had chronic drinking problems 
(Vaillant, 2003). Schutte and colleagues (2003) 
reported on a ten-year follow-up of 292 surviving 
older former problem drinkers (55-65 years of age 
at baseline). They reported that 89% did not report 
any drinking problems throughout the follow-up. 
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Among this group, 37% were abstinent at baseline 
and follow-up and the remainder continued to drink 
alcohol but at lower levels than a comparison group 
of lifetime non-problem drinkers. In Sweden, Ojesjö 
(1981) reported on 15-year follow-up outcomes 
among 96 males with alcohol dependence. Thirty 
per cent were judged recovered, 43% unchanged or 
worse, and 27% had died. Using cross-sectional data 
from a representative sample of US adults (n=4,422), 
Dawson and her colleagues (2005) assessed full and 
partial remission from alcohol dependence among 
those previously diagnosed dependent in the year 
prior to the past year before recruitment to the study. 
The researchers classified the status of this sample as 
follows: 18% were abstainers and 18% were low-risk 
drinkers; 12% were asymptomatic but hazardous 
drinkers, 27% were judged to be in partial remission, 
and 25% were still dependent. Taking these studies 
together suggests that 30-50% of individuals taking 
part in long-term outcome studies will recover from 
alcohol dependence. The recovery rate is higher if non-
symptomatic drinkers are included.
6.5.3 Etter and Stapleton (2006) reviewed 12 
long-term outcome evaluations (from two to eight 
years) of nearly 5,000 people who smoke tobacco 
and have received nicotine replacement therapy (NRT) 
or placebo. In these studies the smoking status of all 
participants treated with NRT was determined after 
12 months. The crude average smoking cessation rate 
was 12% and 18% at longer-term follow-up. When 
including placebo-treated participants, these studies 
indicate that about 30% of quitters at 12 months will 
relapse. The authors suggest the modest long-term 
benefit of NRT suggests that tobacco dependence 
“might be better viewed as a chronic, relapsing 
disorder, requiring repeated episodes of treatment”.
6.5.4 For many people, heroin dependence is 
a remarkably persistent, relapsing disorder which 
can last for decades (Hser et al., 2001). Using illicit 
opioids is also hazardous: international studies point 
to a crude annual mortality rate of about 1-3% 
(Degenhardt et al., 2010), mainly resulting from 
overdose and disease (Darke, 2011). Epidemiological 
studies suggest that up to 50% of dependent users do 
not live beyond their fifth decade and life expectancy 
among survivors is reduced by 18 years. 
6.5.5 That many individuals do completely 
recover from heroin dependence is beyond question. 
Many resolve problems on their own without formal 
treatment. There is also consistent and strong evidence 
that appropriate and well-delivered treatment plays a 
key role in the lives of heroin users and is associated 
with reduced substance use and related problems. 
People retained in treatment have a substantially 
reduced risk of death. In a recent study, Cornish and 
colleagues (2010) reported a crude mortality rate that 
was almost double among opioid users not in treatment 
compared to those in OST (1.3 per 100 person years vs. 
0.7). Compared with the general population of England 
and Wales, the standardised mortality ratio was 5.3 in 
treatment and 10.9 off treatment. 
6.5.6 It should not be expected that a single 
episode of treatment will secure lasting abstinence in 
all but a small minority of drug users. It is the norm for 
an individual to re-enter treatment several times before 
reaching stable remission (three to four episodes have 
been reported in the literature (Anglin et al., 1997; 
Hser et al., 1997). For example, in the USA, Dennis et 
al., (2005) reported on the duration of dependence 
among a heterogeneous sample of 1,326 adults (41% 
male) with substance dependence recruited between 
1996 and 1998 from public addiction services in 
Chicago. Over a three-year follow-up, they looked for 
the point where each participant was able to achieve 
one or more years of abstinence from substance use. 
The median duration of addiction career was 27 years 
and the median treatment career (the time from first 
treatment to one or more years of abstinence) of three 
to four episodes spanned nine years. 
6.5.7 The question of how many people with 
heroin dependence recover is difficult to answer. Few 
studies have tracked heroin users into their fifth and 
sixth decade, and the small literature of longitudinal 
research relates to studies done at different times, in 
different cultures and often using different methods. 
Nevertheless, taken together this research sheds light 
on the course of heroin dependence. It is important to 
note that these studies are also vulnerable to selection 
and differential loss to follow-up leading to bias.
6.5.8 Recently, Calabria and colleagues reviewed 
18 international longitudinal studies that have reported 
remission rates from drug dependence (Calabria et al., 
2010). Ten studies looked at opioids, with a total of 
1,833 participants followed up after three to 33 years 
(the recruited number of participants ranged from 
16-1,000). The remission rate for these studies ranged 
from 23%-93%. Among the larger and longer-term of 
these studies, Hser (2007) reported that 43% of 242 
individuals followed-up after 33 years had been stably 
abstinent from heroin for five years or more. Using 
these ten studies Calabria estimated that the annual 
remission rate (i.e. the proportion expected to become 
abstinent or non-dependent each year) for heroin 
dependence lies between 9% and 22%. 
6.5.9 A notable study from the USA adds 
granularity to this picture. In the late 1970s, William 
McGlothlin and colleagues recruited a sample of 921 
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heroin addicts enrolled in Californian methadone 
maintenance programs and successive research teams 
have followed-up this cohort over three decades. 
After 30 years, nearly half of the original sample was 
deceased. Grella and Lovinger (2011) interviewed 
343 (71%) of the survivors 30 years after recruitment. 
The cohort did not follow a single course over the 
intervening years. Four distinct groups were discernible:
• about 25% of the sample made a relatively rapid 
decrease in heroin use and quit altogether after 
ten to 20 years from initiation
• 15% achieved a more moderate decrease before 
quitting after ten to 20 years
• 25% achieved a gradual decrease in heroin use 
over the 30-year follow-up
• 25% did not reduce their heroin use at all, and 
were still using at follow-up.
6.5.10 Among the rapid and moderate-decrease 
heroin users who attained stable remission (40%), 
18%-25% of their lives were spent enrolled in OST 
(five to eight years). The no-decrease group had the 
highest average time using cocaine (16%) and the 
rapid-decrease group the lowest (6%), and both 
groups had a higher prevalence of psychological and 
personality problems.
6.5.11 A cautious conclusion from this literature is 
that among survivors 40% of heroin users eventually 
attain stable remission (over one to two decades). 
When evaluated after three to five years 20%- 80% 
are likely to be in remission.
6.5.12 However, the research covered by the 
literature reflects the treatment and populations 
primarily of the US and countries other than the UK. 
The appropriate figures for current remission in the UK 
and in particular areas in this country may be markedly 
changed by the profile of the treatment population 
and by the nature of the treatment.
6.5.13 In addition, these figures should not be 
accepted as a basis for future treatment system 
expectations. It is not possible to screen individuals 
for the likelihood of long-term recovery. It is likely 
that there are different factors associated with the 
severity and complexity of each case, and with 
long-term recovery. The literature does suggest there 
is likely to be a subpopulation that achieve rapid 
reductions in heroin use and another subpopulation 
that will be visible early in treatment because of their 
continued heroin use. Treatment providers should 
respond appropriately in each case – for the former 
by exploring ways of strengthening and accelerating 
recovery, and for the latter by conducting a priority 
clinical review with the person on how to personalise 
the treatment plan to secure a reduction in heroin use.
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